Medetomidine Withdrawal in Philadelphia: Health Alert Guidance, Not Trial Evidence
This document is a public health advisory, not a multi-site study, and it gives emergency pharmacists an early, expert-consensus framework for severe withdrawal in people who use fentanyl adulterated with medetomidine.
📅 Journal publication: Jul 8, 2026·Last updated: Nov 5, 2026
medetomidinexylazinefentanylmethadonehydromorphoneclonidinedexmedetomidinealpha-2 agonistopioid withdrawalhealth alerttoxicologyemergency departmentPhiladelphiaEmergency Medicine / Toxicology
Opioid withdrawal complaints soar as MOUD provision drops in EDs.
Increases in opioid withdrawal complaints and decreased medication for opioid use disorder (MOUD) provision in emergency departments (EDs) indicate shifts in withdrawal management due to adulterants. Withdrawal complaints rose from 16.2% to 42.7%, while ED MOUD receipt fell from 46.8% to 27.9% during the study. While the findings highlight increasing withdrawal complaints, the retrospective nature limits applicability to adjust current ED protocols. EDs face rising withdrawal cases; strategies may need reevaluation.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:London KS, Warrick-Stone T, Cherney A, McGann S, Durney P, Goodstein D, Weinstein LC, Randolph F
Citation:London KS, Warrick-Stone T, Cherney A, et al. Emergency Department Opioid Withdrawal Management Across the Alpha-2 Agonist Adulterated Fentanyl Era in Philadelphia, PA: A Multi-Site Study. Substance use & addiction journal. 2026:29767342261459988. doi:10.1177/29767342261459988